Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRBU Caribou Biosciences	$1.92 -3.3%	$1.78	$0.66 ▼ $3.00	$179.26M	2.55	1.33 million shs	721,243 shs
CYBN Cybin	$7.64 -0.4%	$7.65	$4.81 ▼ $13.88	$180.58M	0.68	323,039 shs	264,260 shs
PEPG PepGen	$1.22 -2.0%	$1.28	$0.88 ▼ $10.06	$40.34M	1.19	1.23 million shs	211,244 shs
TVGN Tevogen Bio	$0.91 -1.4%	$1.09	$0.26 ▼ $3.09	$177.43M	-0.77	1.39 million shs	306,676 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRBU Caribou Biosciences	-1.00%	+10.00%	-13.54%	+70.69%	-8.33%
CYBN Cybin	+2.95%	+16.21%	-0.90%	-4.84%	+1,978.59%
PEPG PepGen	-2.36%	+0.81%	-13.29%	-25.75%	-87.04%
TVGN Tevogen Bio	-0.12%	+0.09%	-14.82%	-31.35%	+80.59%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CRBU Caribou Biosciences	2.6571 of 5 stars	3.5	5.0	1.5	1.7	0.0
CYBN Cybin	2.3649 of 5 stars	3.6	0.0	1.8	0.8	1.3
PEPG PepGen	3.3361 of 5 stars	3.2	4.0	2.7	2.5	1.3
TVGN Tevogen Bio	3.8454 of 5 stars	3.5	3.0	2.8	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRBU Caribou Biosciences	3.00	Buy	$6.67	248.13% Upside
CYBN Cybin	3.25	Buy	$85.00	1,012.57% Upside
PEPG PepGen	2.33	Hold	$7.67	531.00% Upside
TVGN Tevogen Bio	3.00	Buy	$10.00	1,002.54% Upside

Current Analyst Ratings Breakdown

Latest PEPG, CRBU, TVGN, and CYBN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2025	TVGN Tevogen Bio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
8/4/2025	TVGN Tevogen Bio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
7/8/2025	CYBN Cybin	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$73.00 ➝ $70.00
6/18/2025	TVGN Tevogen Bio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/10/2025	TVGN Tevogen Bio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
5/29/2025	PEPG PepGen	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$14.00 ➝ $8.00

(Data available from 8/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRBU Caribou Biosciences	$9.99M	17.85	N/A	N/A	$1.78 per share	1.08
CYBN Cybin	N/A	N/A	N/A	N/A	$10.83 per share	N/A
PEPG PepGen	N/A	N/A	N/A	N/A	$2.17 per share	N/A
TVGN Tevogen Bio	N/A	N/A	N/A	N/A	($0.09) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRBU Caribou Biosciences	-$149.10M	-$1.78	N/A	N/A	N/A	-1,800.93%	-62.35%	-49.65%	11/5/2025 (Estimated)
CYBN Cybin	-$57.88M	-$4.60	N/A	N/A	N/A	N/A	-37.58%	-36.59%	N/A
PEPG PepGen	-$89.98M	-$2.96	N/A	N/A	N/A	N/A	-92.51%	-70.39%	11/6/2025 (Estimated)
TVGN Tevogen Bio	-$13.73M	N/A	0.00	∞	N/A	N/A	N/A	-775.49%	11/10/2025 (Estimated)

Latest PEPG, CRBU, TVGN, and CYBN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/19/2025	N/A	TVGN Tevogen Bio	-$0.05	-$0.03	+$0.02	-$0.03	N/A	N/A
8/12/2025	Q2 2025	CRBU Caribou Biosciences	-$0.40	-$0.35	+$0.05	-$0.58	$1.64 million	$2.67 million
8/7/2025	Q2 2025	PEPG PepGen	-$0.85	-$0.70	+$0.15	-$0.70	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRBU Caribou Biosciences	N/A	N/A	N/A	N/A	N/A
CYBN Cybin	N/A	N/A	N/A	N/A	N/A
PEPG PepGen	N/A	N/A	N/A	N/A	N/A
TVGN Tevogen Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRBU Caribou Biosciences	N/A	6.66	6.66
CYBN Cybin	N/A	24.24	24.24
PEPG PepGen	N/A	4.74	4.74
TVGN Tevogen Bio	N/A	0.26	0.26

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRBU Caribou Biosciences	77.51%
CYBN Cybin	17.94%
PEPG PepGen	58.01%
TVGN Tevogen Bio	N/A

Insider Ownership

Company	Insider Ownership
CRBU Caribou Biosciences	8.28%
CYBN Cybin	15.00%
PEPG PepGen	5.20%
TVGN Tevogen Bio	73.24%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRBU Caribou Biosciences	100	93.12 million	85.41 million	Optionable
CYBN Cybin	50	23.59 million	17.96 million	Not Optionable
PEPG PepGen	30	32.80 million	31.09 million	Not Optionable
TVGN Tevogen Bio	3	196.71 million	52.64 million	N/A

PEPG, CRBU, TVGN, and CYBN Headlines

Recent News About These Companies

Tevogen Bio Inc: Tevogen Bio Highlights Proprietary Assets and Upcoming Valuation Disclosure

5 hours ago | finanznachrichten.de

Tevogen Bio Holdings Inc. Highlights Internally Developed Assets Reflecting Long-Term Value

August 27 at 3:30 PM | quiverquant.comQ

Tevogen Bio Highlights Proprietary Assets and Upcoming Valuation Disclosure

August 27 at 3:20 PM | globenewswire.com

Tevogen Expresses Gratitude to Yale for Recognition of Dr. Ryan Saadi and Company’s Mission of Health Equity

August 26 at 5:28 PM | markets.businessinsider.com

Tevogen Expresses Gratitude to Yale for Recognition of Dr. Ryan Saadi and Company's Mission of Health Equity

August 26 at 2:50 PM | globenewswire.com

Tevogen Bio Holdings Inc. Reports 24% Increase in Institutional Ownership in Q2 2025

August 25 at 3:51 PM | quiverquant.comQ

Tevogen Sees Continued Growth in Institutional Ownership in Q2 2025; 72% of Holders Increased or Maintained Positions

August 25 at 3:10 PM | globenewswire.com

Tevogen Recognized in BINJE’s BEST Health Care 2025 for Advancing Health Equity and Sustainable Biopharma

August 22, 2025 | markets.businessinsider.com

Tevogen Bio Holdings Inc. Recognized in BINJE's BEST Health Care 2025 for Commitment to Health Equity and Innovation

August 22, 2025 | quiverquant.comQ

Tevogen Recognized in BINJE's BEST Health Care 2025 for Advancing Health Equity and Sustainable Biopharma

August 22, 2025 | globenewswire.com

Tevogen Bio (NASDAQ:TVGN) Announces Earnings Results

August 21, 2025 | marketbeat.com

D. Boral Capital Reiterates Buy Rating for Tevogen Bio (NASDAQ:TVGN)

August 20, 2025 | marketbeat.com

Tevogen finalizes agreement for up to $50M in financing

August 19, 2025 | msn.com

REPEAT -- Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance ...

August 19, 2025 | bakersfield.comB

REPEAT -- Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts

August 19, 2025 | globenewswire.com

Tevogen Bio Holdings Inc. Reports Q2 2025 Financial Results with Reduced Loss from Operations and Focus on Growth Strategy

August 19, 2025 | quiverquant.comQ

Tevogen Delivers Stronger Second Quarter and First Half 2025 Financial Results with Reduced Expenses and Growth Momentum

August 19, 2025 | globenewswire.com

Tevogen CEO Donates Personal Shares to Support Local Law Enforcement

August 18, 2025 | globenewswire.com

Tevogen CEO Donates Personal Shares to Support Brain Injury Recovery

August 18, 2025 | globenewswire.com

Semper Paratus Acquisition (NASDAQ:TVGN) Stock Price Down 3% - Here's What Happened

August 16, 2025 | marketbeat.com

Tevogen to Release Internal Asset Valuation; CEO Affirms Assets Are Fully Protected

August 14, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PEPG, CRBU, TVGN, and CYBN Company Descriptions

Caribou Biosciences NASDAQ:CRBU

$1.92 -0.07 (-3.28%)

As of 03:41 PM Eastern

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.

Cybin NYSE:CYBN

$7.64 -0.03 (-0.39%)

As of 03:41 PM Eastern

Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds. The company has research and collaboration agreement with TMS Neurohealth Centers Inc. for development of psychedelic compound-based therapeutics; Kernel for use of Kernel flow technology to measure neural activity; and Greenbook TMS to establish mental health centers. The company is headquartered in Toronto, Canada.

PepGen NASDAQ:PEPG

$1.22 -0.03 (-2.02%)

As of 03:39 PM Eastern

PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients. The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. PepGen Inc. was founded in 2018 and is based in Boston, Massachusetts.

Tevogen Bio NASDAQ:TVGN

$0.91 -0.01 (-1.40%)

As of 03:40 PM Eastern

Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time